Tuesday, April 14, 2015

Markers for Oligodendrocyte Progenitor Cells (OPCs)

Improving OPC Expansion

Researchers reference use of Neuromics' GFAP and PDGF R Alpha/CD140A for OPC Selection

The data provided in this publication demonstrates that the OPC yield from SVZ-derived cell cultures can be improved with the PDGF-BB isoform in comparison to classical bFGF-EGF, or PDGF-AA-based protocols. Additionally, it would be expected that the OPC-enriched cultures obtained from NSC/NPC exposure to PDGF-BB and heparin generate cells suitable for cell transplantation for treating demyelinating diseases: Paula G. Franco, Juana M. Pasquini, Lucas Silvestroff. Optimizing Culture Medium Composition to Improve Oligodendrocyte Progenitor Cell Yields In Vitro from Subventricular Zone-Derived Neural Progenitor Cell Neurospheres. Published: April 2, 2015DOI: 10.1371/journal.pone.0121774:

Images: Detection of OPC markers by ICC on NS cells. A) Quantitation of NG2+ and/or PDGFRα+ cell proportions in WT mice NS generated in the presence of different growth factor combinations. Data belong to three independent experiments for each condition. Data for NG2-/PDGFRα- was analyzed with a One-way ANOVA plus Dunnett´s post test, where bFGF/EGF was set as the control. B, C) Representative images of NG2+ and PDGFRα+ cells generated from WT mice cultures in the presence of either bFGF/EGF or bFGF/PDGF-BB. D) Comparison of NG2+ or PDGFRα+ cell proportions in NS cultures generated from Act::EGFP mice in the presence of bFGF/EGF or bFGF/PDGF-BB. Data for NG2+ (dark magenta) or PDGFRα+ (light magenta) cells was analyzed separately with Student´s t test. E, F) NG2 and PDGFRα immunodetection in CNP::EGFP derived cultures. Gray bars in each graph were analyzed with Student´s t test. G) Olig2 expression in WT mice NS cultures. Asterisks are colour coded to indicate the pairs of bars compared and analyzed with Student´s t test. Cell proportions in A, and D-G are expressed as a fraction of the total cell nuclei counted for each condition. Error bars represent the SD for all bar graphs.. doi:10.1371/journal.pone.0121774.g001.

Neuromics has an excellent catalog of Stem Cell Selection Markers.

Monday, April 06, 2015

The Importance of in vivo Like Astroglial-Neuron Co-Cultures

What We Have Learned

I have many posting on both Neuron and Astroglial Cultures. We have now evolved our solution set to include in vivo like co-cultures. These Astroglial Neuron Co-cultures are designed to mimic in vivo like behaviors. They are potent, pure and proven to work in our clients' unique neurodegenerative disease and toxicity drug discovery assays.
Why is this important? The mix of Astrocytes, Glia and Neurons in your co-cultures can impact your data endpoints and lead to inaccurate conclusions. Here're examples as to how much your data can fluctuate. These are data generated from toxicity assays.
We stand ready to serve you and your team. Questions? Don not hesitate to call 612-801-1007 or e-mail me Pete Shuster, CEO and Owner, Neuromics.

Saturday, March 28, 2015

Nestin Expression in Differentiating Neural Progenitors

Breathtaking Images

Our Nestin Antibody + a ​HES5::eGFP reporter was one of the markers used to visualize differentiating stem/progenitor cells (see: Nature Communications 6, Article number: 6500 doi:10.1038/ncomms7500).

Figures: (a) Neural differentiation scheme. Neural induction was performed by a dual SMAD inhibition protocol followed by long-term propagation with the factors indicated for 220 days. Naming conventions representing neuroepithelial (NE), early radial glial (E-RG), midradial glial (M-RG), late radial glial (L-RG) and long-term cultured progenitors (LNP) are indicated. Number of passages are indicated as P(n). (b) Bright field microscopy of progenitor cells during long-term differentiation shows dynamic morphological features. Scale bar: 50 μm (valid for all images in b). (c) Combined ​HES5::eGFP reporter expression and Nestin Immunostainings of stem/progenitor cells.

We have a large catalog of  Neuronal-Glial Markers. They are research proven and frequently published. Should have questions do not hesitate to call me directly 612-801-1007 or Pete Shuster, CEO and Owner.

Monday, March 23, 2015

Neuro-Toxicity Co-Culture

Poster Presentation at Society of Toxicologist Annual Meeting 2015.

As part of Neuromics' strategic selling partnership with ArunA Biomedical. We are attending the SOT 2015 meeting in San Diego, CA.
I am particular excited about our getting the word out on our solutions via poster presentations. Here's the line up:
“In-vitro Human Developmental Neurotoxicity Screening Using Multiple Cell Types"
Anirban Majumder1, Xian Wu2,3, Shelley Wallace1, Jane Le1, Steven L. Stice1,2,3
 1ArunA Biomedical, Inc. Athens, GA, USA, 2Regenerative Bioscience Center, 3Interdisciplinary Toxicology Program, University of Georgia, Athens, GA, USA
Abstract Number/Poster Board number: 636 Poster Board -443
Presentation: March 23, 2015 1:00 PM to 4:30 PM, CC Exhibit Hall 

“Mouse Pluripotent Stem Cell Motor Neurons Generate Robust Neural Network Activity on Microelectrode Arrays"
Steven L. Stice1,2 Anirban Majumder1, Brad Culp1, Anthony M. Nicolini3 and Colin Arrowood3
 Aruna Biomedical Inc. 1, Regenerative Bioscience Center, Univ. of Georgia, Athens GA. 2, Axion BioSystems, Atlanta, GA3
Abstract Number/Poster Board number: 279 Poster Board - 450
Presentation: March 23, 2015 from 9:00 to 12:00 CC Exhibit Hall

 “Bisphenol-A effects on in vitro Human Neural Development was Window of Susceptibility dependent"
Xian Wu1,2, Anirban Majumder3, Steven L. Stice1,2,3
1Interdisciplinary Toxicology Program, 2Regenerative Bioscience Center, University of Georgia, Athens, GA, USA  3ArunA Biomedical, Inc. Athens, GA, USA  
Abstract Number/Poster Board number: 249 Poster Board - 415
Presentation: March 23, 2015 from 9:00 to 12:00 CC Exhibit Hall

“MR Imaging of Human Neural Progenitor Stem Cells: An In Vivo Longitudinal Model "
Forrest Goodfellow, Qingying Ming, Xian Wu, Erin Jordan, Qun Zhao, Steve Stice
Interdisciplinary Toxicology Program, University of Georgia, Athens, Georgia 30602
Abstract Number/Poster Board number: 641 Poster Board -448
Presentation: March 23, 2015 from 1:00 PM to 4:30 PM CC Exhibit Hall 

"Using Human-Derived Neural Cells As an In Vitro Model for Developmental Neurotoxicity following Exposure to Pesticides"
Mary Smith1,2 , Mayowa Amosu, Xiaoming Bian, Kun Lu, Steven Stice2,4 , William Henderson, Shelley WallaceAnirban Majumder4
1Department of Environmental Health Science, University of Georgia, Athens, Georgia, United States; 2 Regenerative Bioscience Center, University of Georgia, Athens, Georgia, United States; 3 ORD/NERL/ERD, U.S. EPA, Athens, Georgia, United States; 4 ArunA Biomedical, Inc., Athens, Georgia, United States
Abstract Number/Poster Board number: 1747 Poster Board - 152
Presentation: March 23, 2015 from 9:00AM  to 12:00 PM 

More to follow...

Tuesday, March 17, 2015

The Power of ISOkine Stem Cell Growth Factors

What Endotoxin, Animal and Serum Free Means to You

ISOkine™ growth factors are produced in barley, bypassing the use of bacterial or animal cell systems.

Why Does this Matter? Proteins produced in bacterial systems contain trace Endotoxins (toxins produced by the bacterial hosts). Studies show that these Endotoxins can compromise health of your stem cell based assays. Animal and human cell expression systems pose risk to your assays, because they may harbor pathogens.

They are Low Cost and Work in the Hands of our Customers: "The ISOKine mouse LIF is an excellent product! I enjoyed dealing with Neuromics. My interactions with Brett were very professional and he assured me the product was guaranteed to work; which it did." Andy Babwah, Children’s Health Research Institute

Product Options:
Catalog #
100 ug
ISOKine-Flt3-Ligand, human-NEW
10 ug
1 mg
H; M
10 ug
50 ug
100 ug
ISOKine-Leukemia Inhibitory Factor (LIF), human-NEW
10 ug
100 ug
1 mg
ISOKine-Leukemia Inhibitory Factor (LIF), mouse-NEW
10 ug
50 ug
100 ug
1 mg
ISOKine-SCF, human-NEW
10 ug
100 ug
1 mg

Should have questions do not hesitate to call me directly 612-801-1007 or Pete Shuster, CEO and Owner.

Friday, March 13, 2015

Curcumin and Aging Health

Cellular Uptake Matters-Not All Curcumin Based Supplements Are Created Equal

There have been many academic publications on the miracles of Curcumin for Aging Health. Here's a description of its therapeutic properties: The desirable preventive or putative therapeutic properties of curcumin have also been considered to be associated with its antioxidant and anti-inflammatory properties. Because free-radical-mediated peroxidation of membrane lipids and oxidative damage of DNA and proteins are believed to be associated with a variety of chronic pathological complications such as cancer, atherosclerosis, and neurodegenerative diseases, curcumin is thought to play a vital role against these pathological conditions. The anti-inflammatory effect of curcumin is most likely mediated through its ability to inhibit cyclooxygenase-2 (COX-2), lipoxygenase (LOX), and inducible nitric oxide synthase (iNOS). COX-2, LOX, and iNOS are important enzymes that mediate inflammatory processes. Improper upregulation of COX-2 and/or iNOS has been associated with the pathophysiology of certain types of human cancer as well as inflammatory disorders. Because inflammation is closely linked to tumor promotion, curcumin with its potent anti-inflammatory property is anticipated to exert chemopreventive effects on carcinogenesis. Hence, the past few decades have witnessed intense research devoted to the antioxidant and anti-inflammatory properties of curcumin. In this review, we describe both antioxidant and anti-inflammatory properties of curcumin, the mode of action of curcumin, and its therapeutic usage against different pathological conditions see: (Adv Exp Med Biol. 2007;595:105-25).

Tuesday, March 03, 2015

The Roots of Anxiety Induced Pain

Corticotropin-Releasing Factor and ERK1/2 Pathway

This study crossed my radar scope because the investigators referenced use of our phosphoERK1/2 for Western Blotting and Immunohistochemistry: Gisela Patrícia da Silva Borges , Juan Antonio Micó Segura , Fani Lourença Moreira Neto , Esther Berrocoso. Corticotropin-Releasing Factor Mediates Pain-Induced Anxiety through the ERK1/2 Signaling Cascade in Locus Coeruleus Neurons. DOI: First published online: 25 February 2015

Conclusion: pain-induced anxiety is mediated by CRF neurotransmission in the LC through ERK1/2 signaling cascade.

Figure: a) Schematic representation of the anatomical pathways implicated. Briefly, the contralateral LC indirectly receives inputs from the inflamed paw (red dashed line; ascending pathways) and, subsequently, the information is sent to corticolimbic areas. Additionally, the LC sends direct projections to the spinal cord (blue straight line; descending pathways). b) Body weight of the control and MA rats. c) Body rectal temperature of control and MA rats. d) Mechanical hyperalgesia represented by a significant decrease in the paw withdrawal threshold of the ipsilateral paw of MA rats. e) Mechanical allodynia represented by a significant decrease in the force threshold of the ipsilateral paw of MA rats. Graph depicting the expression of pERK1/2 in the LC after intra-LC administration of the αCRF receptor antagonist, showing that the significant increase of pERK1/2 in MA4W animals was no longer observed when this antagonist was administered.  g) Graph showing that the local administration of the αCRF antagonist had no significant effect on mechanical hyperalgesia in MA4W rats. h) Graph showing that local administration of h) Graph showing that local administration of the α-helical CRF antagonist had no significant effect on mechanical allodynia in the ipsilateral paw of MA rats. i) Graph showing that the time spent in the open arms decreased in MA4W rats receiving the vehicle alone but this effect was successfully reversed by administration of the αCRF antagonist. j) Graph showing that local administration of the α-helical CRF antagonist had no significant effect on the total distance traveled in the elevated zero maze. k) Graph showing that local administration of the α-helical CRF antagonist reversed the decrease in the number of entries into the open arms observed in MA4W rats receiving the vehicle alone. B=Baseline; LC=Locus Coeruleus; αCRF=antagonist of the corticotropin-releasing factor receptor I and II; W=Week; MA=Monoarthritis.

Western Blotting: The membranes were blocked with 5% Bovine Serum Albumin (BSA; Sigma, Spain) in TBST and probed overnight at 4 ºC with a rabbit anti-phospho-ERK1/2 (1:5,000; Neuromics). Immunohistochemistry: Brains were removed and processed for free-floating immunohistochemistry. One in five sequential transverse brain sections (30 µm) containing the PVN from each rat were washed, blocked and incubated with a rabbit antiserum against the phosphorylated ERK1 and ERK2 isoforms (pERK1/2; 1:1000; 48 hours at 4-8ºC: Neuromics, USA). Immunodetection was achieved with a biotinylated donkey anti-rabbit antiserum (1:500; 1 hour; Jackson ImmunoResearch, USA), followed by an ABC solution (1:200, 1 hour; ABC Elite kit, Vector Laboratories, UK) and a colorimetric reaction with 3,3-diaminobenzidine tetrahydrochloride (DAB; 10 min) in 0.05M Tris-HCl buffer containing 0.003% hydrogen peroxide (Cruz et al., 2005). Sections were then washed in PBS, mounted on gelatin-coated glass slides, cleared in xylene, cover-slipped with DPX and analyzed by light microscopy.

We have a broad range of pain and inflammatory response research markers. Check us out today.

Friday, February 27, 2015

Neurite Outgrowth Assays-96 Well Plates

Fast, Effective and Data Rich!

Our Customers' are reporting great results using our hN2 Primary Human Neurons. We are seeing a natural evolution for high content to high throughput screening. This is because our human neuron culturing kits are proving pure and potent (sample pubs).

Here's some customer data using hN2™ Human Neurons High Throughput Screening (HTS) Kit:

Image: Neurite Outgrowth Assay in 96 Well Plate using hN2 Neurons-Blue – Nuclear staining; Green – Neurite and cell body staining.

Want to learn more? Contact me directly at or 612-801-1007. Thank you. Pete Shuster, CEO and Owner, Neuromics.

Wednesday, February 25, 2015

Neuromics-ArunA Biomedical Partnership

We are Closer than Ever!

I spent the past several days meeting with Ms. Tracey Stice (COO), Dr. Steven Stice (President and CSO) and Ms. Joy Clark (Sales and Marketing Manager) at ArunA HQ in Athens, GA. The objective of the meeting was to finalize plans for our Strategic Selling Partnership. This partnership enables us to open up more cell based assay solutions to current and future Customers involved in neuro-diseases/disorders research and drug discovery.
The Aruna Team

...And the news gets better. By combining our expertise and experience, we are now well positioned to to:
  1. Shape new solutions and services that would more tightly aligned with your unique requirements
  2. Communicate how other labs within your organization are using our solutions and look for ways to leverage this.
  3. Track buying volume so we can give favorable pricing based on purchase made in total by your organization vs specific groups.
We will be working even harder to make sure you that you are satisfied with the value we bring to you and your team. Wondering what we can do for you today? You can contact me directly 612-801-1007 or Thank you. Pete Shuster, CEO, Neuromics AND ArunA Biomedical Strategic Selling Partner.

Saturday, February 21, 2015

i-Fect Delivers siRNA in vitro and in vivo

Gene Expression Analysis for Studying Stroke

We have posted over 35 publications that reference use of our i-Fect Transfection Kit to deliver siRNA, miRNA and shRNA in vitro and in vivo. Results documented in these publications prove that this kit is both non-toxic and delivers ultra-high transfection efficiency.

i-Fect Data Example

Figure. The effects of HDAC2 siRNA Infusion into the CeA of P rats on voluntary ethanol consumption as measured by the two-bottle free choice paradigm. Monitoring the voluntary ethanol consumption of alcohol-preferring (P) rats via the two bottle free choice paradigm following infusion of vehicle or histone deacetylase isoform 2 (HDAC2) siRNA into the central amygdala (CeA) demonstrates that high HDAC2 levels may mediate the high alcohol drinking behaviors of P rats. P rats were given access to water and 7% ethanol followed by water and 9% ethanol. On the sixth day of ethanol access P rats received infusion of vehicle or HDAC2 siRNA and consumption of water and 9% ethanol were monitored for sevnfusion. Total fluid intake did not significantly differ between the groups. Values are represented as the mean ± SEM of the ethanol consumption (g / kg / day) and total fluid intake (mL) plotted daily for n=6 rats per treatment group. *Significantly different between the groups.SACHIN MOONAT. The Role of Amygdaloid Chromatin and Synaptic Remodeling in Anxiety and Alcoholism. THESIS Submitted as partial fulfillment of the requirements for the degree of Doctor of Philosophy in Neuroscience in the Graduate College of the University of Illinois at Chicago, 2014.

Here's yet another recent publication highlighting use of i-Fect:

In this study data suggest the protective effects of EPO on NUV injuries are highly associated with the increase of p-Cx43, which improves GJIC to reduce neurotoxic substances: Ziyi Zhoua, Xiaobai Weib, Jun Xiang, Junpeng Gao, Lixin Wang, Jinsong You, Yefeng Cai , Dingfang Caid. Protection of erythropoietin against ischemic neurovascular unit injuries through the effects of connexin43. Biochemical and Biophysical Research Communications. doi:10.1016/j.bbrc.2015.02...The strands were incubated at 90°C for 5 min and then at 37°C for 1 h. SiRNA was prepared immediately before administration by mixing the RNA solution (1 μg/μl in annealing buffer) with the transfection reagent i-Fect (v/v: 1/3; Neuromics, Edina, MN, USA) to a final siRNA ...

•EPO has protective effects on ischemic NVU injuries.
•EPO up-regulates phosphorylation of Cx43, not total Cx43.
•EPO's protective effects on NUV injuries are p-Cx43-GJIC dependent.

Wednesday, February 11, 2015

Proven and Published Sandwich ELISA Kits

Growing Catalog of ELISA Kits

We are partnering with RayBiotech to manufacture our ELISA Kits. They have proven valuable additions to our Cell Based Assay solutions.

Neuromics has been built on a foundation of quality. RayBiotech's commitment to quality includes compliance to GLP/GMP FDA and ISO9000 regulations.
ELISA Kits Sample Data

Figure: Induction of proinflammatory cytokines is attenuated in CX3CL1−/− mice expressing sFKN. TNFα and IL-1β concentrations were measured using standard ELISA techniques for VM lysates. a, TNFα concentrations were upregulated following MPTP administration (three-way ANOVA; F(1, 23) = 18.36, ★★★p < 0.001). Comparatively, CX3CL1−/− mice expressing sFKN in the SNpc had significantly lower concentrations of TNFα relative to mFKN (Tukey's HSD; ***p < 0.001) and GFP (Tukey's HSD; ###p < 0.001) expressing mice. There were no significant differences between sFKN and WT-MPTP (Tukey's HSD; p = 0.384) or mFKN and GFP (Tukey's HSD; p = 0.773). b, The IL-1β concentrations in the VM were significantly upregulated for mice exposed to MPTP (three-way ANOVA; F(1, 23) = 11.97, ★★★p = 0.002). Similar to the pattern of TNFα, IL-1β concentrations in CX3CL1−/− mice expressing sFKN were significantly blunted compared to both mFKN (Tukey's HSD; ***p = 0.001) and GFP (Tukey's HSD; ###p < 0.001). As was observed with TNFα, there were no significant differences in IL-1β concentrations between WT-MPTP and sFKN (Tukey's HSD; p = 0.785) or mFKN and GFP (Tukey's HSD; p = 0.845) expressing mice. Data are presented as the mean ± SEM.

Questions? Please contact me directly, Pete Shuster, CEO and Owner, 612-801-1007 or Thank you.

Saturday, February 07, 2015

Your Feedback Matters

Our Solutions Must Work

We take our ability to serve you very seriously. We use bird-eye to make sure each and every one of our customers are pleased with results. If you are not happy, we do everything we can to fix your issue. This includes replacement and refunds:
Should you ever have questions or issues, I am at your "beck and call". Do not hesitate to contact me directly. Pete Shuster, CEO and Owner, Neuromics, 612-801-1007 or Thank you!

Saturday, January 31, 2015

Neural Progenitors and Cool Science

Titania Nanotubes and Neural Prostheses

I am always on the hunt for the use of our Neural Progenitor Markers in cool and important human health applications. Here our Nestin Antibody is use to access the growth and maintenance of C17.2 neural stem cell line cultured in these nanotubes: Jonathan A. Sorkin, Stephen Hughes, Paulo Soares, Ketul C. Popat. Titania nanotube arrays as interfaces for neural prostheses. Materials Science and Engineering: C Volume 49, 1 April 2015, Pages 735–745. doi:10.1016/j.msec.2015.01.077

Image: Nestin staining eSC Derived hNP1 Human Neural Progenitors. Cells were stained using goat anti-mouse Alexa Fluor 488 secondary antibody (green) (Molecular Probe, A-11001) and counterstained with DAPI (blue).

Abstract: Neural prostheses have become ever more acceptable treatments for many different types of neurological damage and disease. Here we investigate the use of two different morphologies of titania nanotube arrays as interfaces to advance the longevity and effectiveness of these prostheses. The nanotube arrays were characterized for their nanotopography, crystallinity, conductivity, wettability, surface mechanical properties and adsorption of key proteins: fibrinogen, albumin and laminin. The loosely packed nanotube arrays fabricated using a diethylene glycol based electrolyte, contained a higher presence of the anatase crystal phase and were subsequently more conductive. These arrays yielded surfaces with higher wettability and lower modulus than the densely packed nanotube arrays fabricated using water based electrolyte. Further the adhesion, proliferation and differentiation of the C17.2 neural stem cell line was investigated on the nanotube arrays. The proliferation ratio of the cells as well as the level of neuronal differentiation was seen to increase on the loosely packed arrays. The results indicate that loosely packed nanotube arrays similar to the ones produced here with a DEG based electrolyte, may provide a favorable template for growth and maintenance of C17.2 neural stem cell line.

I will continue to how our stem cell solutions are used in cool, new discoveries.

Friday, January 30, 2015

Sensitive, Specific and Cost Effective Protein Expression Analysis

Reaching for Cell Based Assay Solutions Excellence

We have been receiving positive feedback from clients using our Quantibody® and RayBio® C-Series Membrane-Based Antibody Arrays. Our manufacturing partner, Raybiotech, is ISO 9000 certified insuring all arrays are made to exacting specification. The cost for measuring a single cytokine runs as low as 16 USD/Cytokine!

We use these arrays to test the blood serum of clients with autoimmune diseases to determine levels of cytokine and growth factor expression vs healthy controls. We also use them to determine proteins secreted by our  USB Derived hMSCs cultured in our hMSC Media. This gives us insight as to the protein expression patterns in our hMSC, Chondrogenesis and Osteogenesis Assays.

Figure: The graph shows cytokine secretion of hMSCs after a continuous 24 day culture. These results were obtained using our select markers from our cytokine and bone metabolism arrays. Data courtesy of Dr. Jim Musick and Tiana Tonrey, Vitro Biopharma.

We are pleased to announce the addition of these new human and mouse arrays:

Quantibody® Human Growth Factor+Neurotrophin+Cytokine Array Q1-10. Precisely measures: Amphiregulin, BDNF, bFGF, BMP-4, BMP-5, BMP-7, beta-NGF, EGF, EGFR, EG-VEGF (PK1), FGF-4,FGF-7 (KGF), GDF-15, GDNF, Growth Hormone, HB-EGF, HGF, IGFBP-1, IGFBP-2, IGFBP-3, IGFBP-4, IGFBP-6, IGF-1, Insulin, M-CSF R, NGFR (TNFRSF16), NT-3, NT-4, Osteoprotegerin (TNFRSF11B), PDGF-AA, PLGF, SCF, SCF R (CD117/c-kit), TGF alpha, TGF beta 1, TGF beta 3, VEGF-A, VEGFR2, VEGFR3 and VEGF-D.
Mouse C-Series Cytokine Array. C1-2-Semi-quantitavely measures: GCSF,GM-CSF, IL-2, IL-3, IL-4, IL-5, IL-6, IL-6, IL-9, IL-10, IL-12 p40/p70, IL-12 p70, IL-13, IL-17A, IFN-gamma, MCP-1 (CCL2), MCP-5, RANTES (CCL5), SCF, TNF RI (TNFRSF1A), TNF alpha, Thrombopoietin, (TPO) and VEGF-A.

Images: Representative images obtained with RayBio® C-Series Antibody Arrays. These membranes were probed with conditioned media from two different cell lines. Membranes were exposed with Kodak X-Omat® film at room temperature for 1 minute. Note the strong signals of the Positive Control spots in the upper left and lower right corners.

Questions? Do not hesitate to contact me: or direct phone-612-801-1007. Thank you. Pete Shuster, CEO and Owner, Neuromics

Tuesday, January 27, 2015

Human Growth Factor+Neurotrophin+Cytokine Array-Test 40 Markers in on Assay

Sensitive, Specific and Cost Effective

Neuro-immuno and degenerative diseases and disorders commonly show dysregulation of Growth Factors and Cytokines. Using our Quantibody Neuroscience Arrays, we have measured the blood serum of clients with Neuro-inflammatory/immune response diseases/disorders including Autism Spectrum Disorder (ASD). Most showed lowered levels of Growth Factors/Neurotrophins and elevated levels of Inflammatory Response Cytokines.

In order to expand the number of biomarkers measured, we are pleased to announce the addition of our New Growth Factor+Neurotrophin+Cytokine Array. This will enable us to further determine the "finger prints" of these diseases/disorders at the protein level. This array includes: Immunogen: Amphiregulin, BDNF, bFGF, BMP-4, BMP-5, BMP-7, beta-NGF, EGF, EGFR, EG-VEGF (PK1), FGF-4,FGF-7 (KGF), GDF-15, GDNF, Growth Hormone, HB-EGF, HGF, IGFBP-1, IGFBP-2, IGFBP-3, IGFBP-4, IGFBP-6, IGF-1, Insulin, M-CSF R, NGFR (TNFRSF16), NT-3, NT-4, Osteoprotegerin (TNFRSF11B), PDGF-AA, PLGF, SCF, SCF R (CD117/c-kit), TGF alpha, TGF beta 1, TGF beta 3, VEGF-A, VEGFR2, VEGFR3 and VEGF-D.

I will continue to post testing results here.

Monday, January 19, 2015

Solutions for Studying Neuro-degeneration

Data Rich and Frequently Published

The Neuromics' brand is built, in part, by our proven ability to provide solutions for the study of neuro-degeneration. These include:
A recent example shows the use of one of  MAP-2 markers to study hearing decline with age: Radtke-schuller S, Seeler S and Grothe B(2015) Restricted loss of olivocochlear but not vestibular efferent neurons in the senescent gerbil (Meriones unguiculatus). Front. Aging Neurosci. 7:4. doi:10.3389/fnagi.2015.00004.

Figure: Lipofuscin granules in MSO neurons of an aged gerbil. MSO neurons are MAP2 immunostained (Alexa Fluor 647, red). Lipofuscin granules have been excited with the DAPI excitation wavelengths and appear blue. Confocal images show a maximum projection of image stacks in A and a single optical image of 0.3 µm thickness in the enlargement in B. Scale bar in A: 50 µm and 20 µm in B.

We stand ready to serve you. Should you have interest or questions, do not hesitate to contact me directly: Pete Shuster-Owner/ or direct phone: 612-801-1007. Thank you.

Monday, January 12, 2015

Cancer Associated Fibroblasts (CAFs)-Flow Cytometry and Immunostaining Results

If they Walk and Talk Like CAFs, They Are!

We are experiencing growing demand for are CAFs. They are closely associated with primary tumor cells and participate in the neoplastic process. There is reciprocal communication between CAFs and tumor cells through paracrine effects of secreted growth factors, cytokines & chemokines from both fibroblasts, tumor cells and other tumor-associated cells.

Potential users are asking how well the cells are characterized. The purpose of this posting is to share key gene expression data:
Table: expression of key proteins
Images: Human Lung Adenocarcinoma CAFs stained with Vimentin, aSMA, b-Catenin and DAPI (blue),

Cancer Associated Fibroblasts Gene Expression Data(pdf - 784Kb)-Flow Cytometry and Immunostaining Results.
Questions? Please contact me directly-Pete Shuster- CEO & or 612-801-1007.

Monday, January 05, 2015

Racing into 2015

Thank you for a Great 2014!
EU PCWow. I would like to thank our customers, collaborators and friends for helping us achieve unprecedented success in 2014.

We plan on racing hard into 2015. I would like to highlight our focus areas for the New Year.

Stem Cell Activating Solutions-We have been pilot testing solutions foir balanced immunity and stem cell vitality. Our clients have been mostly peopole with autoimmune related issues. After 6 months of therapy, the improvement in symptoms and test results, for many, has been stunning (see below).
We have developed migration and other assays to test these solutions in vitro using our UCB Derived hMesenchymal Stem Cells. We also use medical testing to prove and improve their therapeutic value. These assays and arrays are available for labs and clinics interested in testing stem cell related solutions. Here're representative data from our Quantibody Array testing program.

Stem and Primary Cell Based Assays-We will continue to add new solutions for your assays. These will include mixed culture that more closely mimic in vivo environments like mixed astroglial-neuron cultures. Below is our hN2TM Human Neurons stained with one of our neuron markers.
Image: hN2 cells grown in culture for 4 days and stained with our chicken polyclonal to Neurofilament light or low molecular weight chain NF-L, a marker of neurons. Many of the differentiating cells show strong cytoplasmic and clearly fibrillar staining for NF-L. Blue stain is DAPI and reveals cell nuclei of some non neuronal cells in this culture.

Check out and join my Stem Cell Clinical Trails Group on Linkedin (4500+members strong).
We wish you a rewarding 2015.

Pete Shuster-
CEO & or 612-801-1007

Wednesday, December 24, 2014

immunoLink Therapies and Treating ASD Children

6-Months of Therapy and Testing Results

I have previously posted our testing and treatment regime for ASD Children. For some of the children, we are seeing marked improvement after 6 months of our treatment regime using solutions aimed at balance immunity and stem cell vitality.

We find that for the children we treat all have varying dysregulated levels of immune/inflammatory response, oxidative stress and growth factor/neurotrophin biomarkers.  We customize treatment plans based on pre-treatment testing results. We then re-test after 6 months to see the level of moderation in these biomarkers/factors. The re-tests are used to show the parents how well these children are responding to treatment and to further adjust plans.

Here I would like to share the results from our more traditional medical testing. These are representative results from one of the Children we are treating.
Graph: ASD Child Pre-treament and 6 month treatment analyte levels vs healthy sweet spots

If you are interested in learning more, please contact me directly (612-801-1007) or Pete Shuster, CEO and Owner of Neuromics and ImmunoLinkTMTherapies.

Thursday, December 18, 2014

immunoLink Therapies-Initial Products

Feeling and performing your best depends on balanced immunity and stem cell vitality

Your current investment in exercise, healthy diet and supplements are aiming you towards what we call the immunoLink sweet spot. If you have hit the bull’s eye, you would be seeking ways to stay there, because this is where you feel awesomely great and are most productive. If you have never been there, now is the time.

Illness, injury and medical procedures push you from the spot, but if you are near or on it, your recovery will be faster and more complete. The far reaches of the immunoLink Spectrum represent a cold wasteland of misery and despair.

How do we Know These Solutions Work?-Our Clients have autoimmune and degenerative diseases or are seeking peak performance. Prior to customizing their treatment strategies, we measure the levels of immune/inflammatory response, oxidative stress, allergens and stem cell health factors in our Clients' blood serum. The levels of these factors are compared with healthy controls. We then re-test after 6 months of treatments. For many the improvement in health and performance are startling. This is confirmed in the re-tests.
Stem-Kine and StemTrophin are central to our treatment strategies. Stem-Kine boosts the levels of circulating blood stem cells. These cells differentiate into immune factors and red blood cells. This boosts oxygen delivery and immunity resulting in greater endurance, mental acuity and cardiovascular health. StemTrophin activates mesenchymal stem cell migration. These cells are essential for immune suppression and then initiating the process of repair and regeneration at the sites of injury or degeneration. To learn more or order by phone, please call me directly at 612-801-1007 or you can also inquire via my e-mail: Pete Shuster, CEO and Owner, Neuromics and immunoLink Therapies.

Monday, December 15, 2014

Stem Cell Based Therapy For Tendinosis

Using Collagen I Producing Cells from Hair Follicles

Learn how these cells can be these cells can be harvested, purified and expanded to treat a chronic, degeneration of tendons.

Saturday, December 06, 2014

Treating Autism-Immune System Balancing and Stem Cell Activating Therapies

Linking the Immune System with Stem Cell Health to Treat ASD Children

We have been testing immune/inflammatory response, oxidative stress and growth factor/neurotrophin biomarkers in the blood sera of Children with Autism Spectrum Disorder (ASD). We did this testing using our Quantibody Arrays.

The purpose of these tests were to establish a baseline for the state of these children's immune system and stem cell health. In this baseline testing, we found that all had high immune/inflammatory response, oxidative stress and low levels of the growth factors/neurotrophins needed for repairing and regenerated damaged cells/tissue (stem cell health).

We then treated these children with customized combinations of immune balancing and stem cell activating agents with the goal of showing that any improvement in ASD related symproms would be confirmed by positive modulations of biomarkers that are dysregulated in this disorder. We re-test at 6 months after initiation of the treatment plans.

The goal of our treatment strategies is to balance the immune system and activate the natural cell/tissue repair and regeneration (stem cell) processes. We call this the immunoLinkTM.

We are seeing improvement in the symptoms of the first 2 children recently retested and a marked improvement in the levels of their biomarkers. Here's data from one of the children. Note that key immune/inflammatory response markers have now moderated to the levels of healthy controls.

Graphs: Comparison of initial testing (red) and 6 month re-test (green) vs healthy controls (blue) for one of our ASD Children

We are developing a website that will have a wealth of information to help parents determine treatment strategies for ASD Children. We are also making our treatment plans and strategies available to interested parents. The website ecosystem will be named immunoLinkTM Therapies.
In the meantime, should you want to investigate if we could help your child, do not hesitate to contact me e-mail: or cell: 612-801-1007. Pete Shuster, CEO and Owner.

Monday, November 24, 2014

Good Axon; Bad Axon: Regeneration in the CNS and Age

"The incapacity of the central nervous pathways to regenerate is a dogma accepted by science..." - Ramon y Cajal

Harvard University has opened access to Michio Wendell Painter's Dissertation: Regeneration in the aging peripheral nervous system. Will Spinal Cord Injury (SCI) and Neurodegenerative Diseases of the PNS become treatable with regenerative therapies? This work provides important insights.

Age plays a central role in regenerative capacities.

Monday, November 17, 2014

Neuropathy Research Solutions

New Publications and Past Postings

Here're are several key postings on Neuropathy and Neuropathic Pain:
Here're some "hot of the press" publications referencing use of Neuron-Glial Markers
Bethany L. Johnson-Kerner, Faizzan S. Ahmad, Alejandro Garcia Diaz, J. Palmer Greene, Steven J. Gray, R. Jude Samulski, Wendy K. Chung, Rudy Van Coster, Paul Maertens, Scott A. Noggle, Christopher E. Henderson and Hynek Wichterle. Intermediate filament protein accumulation in motor neurons derived from giant axonal neuropathy iPSCs rescued by restoration of gigaxonin. Hum. Mol. Genet. (2014) doi: 10.1093/hmg/ddu556. First published online: November 4, 2014.
...MAP2 (1:2,000, Neuromics, CH22103), NF-H (1:2000, Neuromics, CH22104), NF-L (1:200, Neuromics, MO22104)...

Images: Cells grown from adult rat brain. Large cell in middle is stained with mouse monoclonal to NF-L clone DA2 (green). Another type of neuronal lineage cell was stained with rabbit polyclonal to alpha-internexin (red). These cells were mitotic but had several characteristics of neurons. Rat spinal cord homogenate showing the major intermediate filament proteins of the nervous system (lane 1). The remaining lanes show blots of this material stainted with various antibodies including: NF-H, NF-M,, NF-L,, NF66 and GFAP 

Jianfei Guo, Xudong Fu, Xia Cui, Minhua Fan. Contributions of purinergic P2X3 receptors within the midbrain periaqueductal gray to diabetes-induced neuropathic pain. The Journal of Physiological Sciences November 2014.
...An equal volume of total and membrane samples was applied to SDS-PAGE. Membranes were incubated with the rabbit anti-P2X 3 primary antibody (1:1000, Neuromics, Edina, MN, USA) and goat anti-rabbit secondary antibody (1:200, Neuromics, Edina, MN, USA).

Neuropathy Research Solutions Include:

Friday, November 14, 2014

Immune System/Stem Cell Health and Aging

Looking, feeling and  performing your best depends on balanced immunity and stem cell vitality

As we age we encounter:
  • Slower healing
  • Longer recovery time from vigorous exercise
  • More general aches and pains
  • Longer recovery from illness
  • Wrinkled, dry and thinning skin
Why is that? What are the causes? Answers can be found by a better understanding of immune/inflammatory response and stem cell systems. As we age our immune system weakens or becomes dysregulated (autoimmunity) and our stem cell "bank balances" deplete. My friend and world class stem cell therapies expert, Dr. Neil Riordan, gives an excellent description of the process: Your Body’s Stem Cell Bank Account.

To oversimplify, the immune system is responsible for cleansing the body of pathogens, toxins, allergens and damaged tissues/cells. This creates a healthy environment for stem cells to repair and regenerate new, healthy cells and tissue. We call this process the immunoLinkTM.

immunoLink Therapies is a new company of mine slated to launch in the spring of 2015. Our goal is to slow the aging process by offering solutions that balance your immunity and increase your stem cell vitality. Our vanguard product (currently available) is Stem-Kine. It is a blood stem cell booster which increases the level of immune factors and red blood cells in your cardiovascular system. The result is faster healing/recovery and increased endurance via better oxygen delivery.

If you desire to learn more, do not hesitate to call (612-801-1007) or e-mail: Thank you. Pete Shuster

Saturday, November 01, 2014

GFP Labeled Mouse Motor Neurons-Buy Now Save 100 USD

Designed for Motor Neuron Disease Research

I am pleased to add (finally) to our catalog potent, pure and ready to culture motor neurons. I know from the many request I have gotten for these that demand could be out stripping supply.

These are designed foruse in High-throughput fluorescent screening applications. Derived from transgenic mice expressing eGFP using Hb9 motorneuron promoter enables easy tracking and vi sualization of spinal motor neurons without the need for additional fluorescent markers and extended cultures.

Image: GFP+ mMN Mouse Motor Neurons at 2 days post thaw 20X

If you want to learn more about our any of our Neuron-Glial-Astrocyte Based Assay Solutions, do not hesitate to contact me (612-801-1007) or Pete Shuster, Owner and CEO, Neuromics.